Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023
02. Mai 2023 02:00 ET
|
Verona Pharma plc
12 Abstracts and one Symposium further support potential of ensifentrine,a first-in-class, selective, dual inhibitor of PDE3 and PDE4 Conference call May 23 at 4:00 p.m. EDT / 9:00 p.m. BST LONDON...
Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update
25. April 2023 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., April 25, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD
10. April 2023 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., April 10, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
07. März 2023 02:00 ET
|
Verona Pharma plc
Transformational results in Phase 3 ENHANCE program for COPD NDA submission expected Q2 2023 Strong balance sheet to support planned US commercial launch Conference call today at 9:00 a.m. EST /...
Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
21. Februar 2023 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD
20. Dezember 2022 02:00 ET
|
Verona Pharma plc
Statistically significant improvements in lung function, symptoms and quality of life 36% reduction in rate of exacerbations over 24 weeks Well tolerated safety profile over 48 weeks NDA submission...
Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-1 Trial of Nebulized Ensifentrine for COPD
19. Dezember 2022 16:01 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update
09. November 2022 02:00 ET
|
Verona Pharma plc
Access to up to $400 million expected to provide cash runway through at least 2025 Top-line Phase 3 ENHANCE-1 data expected around the end of 2022 Conference call today at 9:00 a.m. EST / 2:00 p.m....
Verona Pharma Announces November 2022 Investor Conference Participation
02. November 2022 03:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will participate in the following...
Verona Pharma to Report Third Quarter 2022 Financial Results and Provide Corporate Update
26. Oktober 2022 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...